Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record.

Treatment of Gram-positive Nosocomial Pneumonia: Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin

FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., LILIENTHAL, F., the Nosocomial Pneumonia Group·2000·American Journal of Respiratory and Critical Care Medicine

Abstract

Nosocomial pneumonia is a frequent complication in hospitalized patients. Gram-positive pathogens, particularly Staphylococcus aureus, are responsible for the increasing frequency of nosocomial pneumonia. To evaluate the efficacy and safety of intravenous quinupristin/dalfopristin (Synercid) in the treatment of nosocomial pneumonia caused by gram-positive pathogens we conducted a prospective, randomized, open-label, international, multicenter, comparative clinical trial. Two hundred ninety-eight patients with nosocomial pneumonia were enrolled in 74 active centers in five countries: a subgroup of 171 (87 quinupristin/dalfopristin-treated and 84 vancomycin-treated patients) were evaluable for the major efficacy end points. One hundred fifty received 7.5 mg/kg of quinupristin/dalfopristin every 8 h; 148 patients received 1 g of vancomycin every 12 h. Aztreonam at a dose of 2 g every 8 h could be administered in both groups for coverage of gram-negative organisms, and tobramycin was added for coverage against Pseudomonas aeruginosa. The primary efficacy end point was the clinical response between the seventh and the thirteenth day after the end of treatment in clinically evaluable patients with documented causative pathogen(s) at baseline (bacteriologically evaluable population). Therapy was clinically successful (cure or improvement) in 49 (56.3%) of patients receiving quinupristin/dalfopristin and 49 (58.3%) patients receiving vancomycin (difference, -2.0% [95% CI, -16.8% to 12.8%]) in the bacteriologically evaluable population. Equivalent clinical success rates were also observed in the all-treated population (n = 298), and in the bacteriologically evaluable patients intubated in baseline (39/72 [54%] compared with 36/67 [54%]). The by-pathogen bacteriologic response was similar in both treatment groups, with equivalent clinical success rates for Streptococcus pneumoniae, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus. Adverse events (venous and nonvenous) were equally distributed between groups; 15.3% of quinupristin/dalfopristin patients and 9.5% of vancomycin patients discontinued therapy because of an adverse clinical event. In this study quinupristin/dalfopristin was shown to be equivalent to vancomycin in the treatment of nosocomial pneumonia caused by gram-positive pathogens. Quinupristin/dalfopristin merits further evaluation for the treatment of nosocomial pneumonia caused by methicillin-resistant S. aureus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm.161.3.9904115

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 214

Metadata

Authors
FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., LILIENTHAL, F., & the Nosocomial Pneumonia Group
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2000-03-01
Volume
161
Issue
3
Pages
753-762
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1867064160
Cited by
214
References
0
FWCI
12.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Gram-positive Nosocomial Pneumonia: Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin. https://app.cochat.ai/papers/10.1164/ajrccm.161.3.9904115
The paper
FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., LILIENTHAL, F., & the Nosocomial Pneumonia Group. (2000). Treatment of Gram-positive Nosocomial Pneumonia: Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.161.3.9904115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.